UNSPSC 51431506: Eprosartan mesilate or mesylate

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C23H24N2O4S.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8N2L1NX8S3, chemically known as (e)-2-butyl-1-(p-carboxybenzyl)-.alpha.-2-thenylimidazole-5-acrylic acid, monomethanesulfonate, but more generally known as eprosartan mesylate, which bears US NIH Compound Identifier 5282474.

UNSPSC 51431506 Eprosartan mesilate or mesylate is a Commodity code representing a single pharmaceutical product line that state and local governments procure as part of broader advanced life support medication and generic pharmaceutical supply contracts. State and local buyers—including municipal fire rescue services, state health agencies, and cooperative purchasing alliances—source this medication through standard pharmaceutical procurement channels alongside other injectable medications, generics, and over-the-counter products. The work involves supplying FDA-compliant medications with specified expiration windows, managing cold-chain logistics where required, and meeting regulatory documentation standards including Safety Data Sheets, Good Manufacturing Practices certification, and Drug Supply Chain Security Act compliance. Issuing bodies span municipal fire departments (such as Tampa Fire Rescue), state health commissions (such as Texas HHS), and multistate cooperative purchasing organizations (such as MMCAP), with purchasing coordinated through authorized pharmaceutical wholesalers or direct procurement offices.

Recent activity appears concentrated in Texas and Florida, with multistate cooperative procurement activity spanning Minnesota and Oregon. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications due April 8, 2026, requesting 1,810 units of Epinephrine 1:10,000 injections alongside Labetalol, Adenosine, and Diltiazem for Tampa Fire Rescue—an estimated $40,000 contract with a one-year term and options to renew for two additional years. The Texas Health and Human Services Commission posted an RFI (No. HHS0017013) on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager channels, though this remains exploratory and does not yet identify specific medication line items or award values. The Minnesota Department of Administration issued an RFP through MMCAP on January 20, 2026, with response due March 26, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson), with contract effectiveness July 1, 2026, and a two-year initial term. Procurement activity under this code reflects routine supply-chain replenishment rather than program-level expansion or emergency scaling.